Trial Profile
A study of injectable formulation of DUR-928 in patients with moderate and severe acute liver function impairment.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Larsucosterol (Primary)
- Indications Liver disorders
- Focus Adverse reactions; Pharmacokinetics
- 08 Nov 2017 New trial record